Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of odanacatib to prevent bone metastases in castration-resistant prostate cancer
2008-002120-29Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and bone metastases comparing Odanacatib 5 mg once daily with Placebo once daily (2 arms). Primary endpoint: Time to first bone metastasis or death (bone metastasis-free survival). Started Jun 2008; status: terminated.
02
Drugs
odanacatib
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on 2008-002120-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002120-29.